Your browser is no longer supported. Please, upgrade your browser.
KALV KalVista Pharmaceuticals, Inc. daily Stock Chart
KALV [NASD]
KalVista Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.64 Insider Own2.30% Shs Outstand17.84M Perf Week10.05%
Market Cap206.65M Forward P/E- EPS next Y-2.79 Insider Trans-0.09% Shs Float16.14M Perf Month-4.89%
Income-29.10M PEG- EPS next Q-0.61 Inst Own93.70% Short Float2.67% Perf Quarter9.94%
Sales12.70M P/S16.27 EPS this Y-18.80% Inst Trans0.06% Short Ratio3.14 Perf Half Y-31.51%
Book/sh4.69 P/B2.41 EPS next Y-4.10% ROA-27.20% Target Price- Perf Year-28.56%
Cash/sh3.70 P/C3.05 EPS next 5Y- ROE-31.20% 52W Range5.61 - 18.96 Perf YTD-36.66%
Dividend- P/FCF- EPS past 5Y33.10% ROI-48.20% 52W High-40.66% Beta2.39
Dividend %- Quick Ratio11.50 Sales past 5Y237.50% Gross Margin- 52W Low100.71% ATR0.78
Employees56 Current Ratio11.50 Sales Q/Q31.00% Oper. Margin- RSI (14)47.64 Volatility8.03% 6.11%
OptionableNo Debt/Eq0.00 EPS Q/Q25.60% Profit Margin- Rel Volume0.14 Prev Close11.28
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume136.91K Price11.25
Recom1.50 SMA20-3.46% SMA50-2.29% SMA200-9.30% Volume8,311 Change-0.27%
Jun-15-20Initiated H.C. Wainwright Buy $30
Jul-29-19Initiated SVB Leerink Outperform $31
Mar-20-19Initiated Needham Buy $35
Oct-30-18Initiated Jefferies Buy $30
Sep-21-18Initiated Cantor Fitzgerald Overweight
Aug-31-17Initiated BTIG Research Buy $18
Aug-03-20 07:30AM  
Jul-02-20 07:55AM  
Jul-01-20 07:00AM  
Jun-23-20 07:04PM  
Jun-15-20 09:57AM  
May-28-20 07:30AM  
Apr-20-20 08:42AM  
Apr-13-20 01:44PM  
Apr-09-20 07:00AM  
Apr-07-20 07:00AM  
Mar-10-20 07:30AM  
Feb-21-20 02:25PM  
10:22AM  
Feb-19-20 07:30AM  
Feb-18-20 09:46AM  
Feb-13-20 10:03AM  
Feb-12-20 09:45AM  
Feb-11-20 07:23AM  
Feb-10-20 04:30PM  
Feb-05-20 08:35AM  
Feb-04-20 08:15AM  
Feb-03-20 11:54AM  
Jan-23-20 11:44AM  
05:29AM  
Jan-21-20 08:41AM  
Jan-13-20 07:00AM  
Jan-06-20 08:29AM  
Jan-02-20 07:24AM  
Dec-12-19 07:37PM  
Dec-09-19 07:00AM  
Dec-06-19 07:42AM  
Dec-05-19 09:57AM  
Dec-03-19 07:30AM  
Nov-13-19 07:30AM  
Nov-07-19 06:08AM  
Nov-06-19 03:01PM  
Oct-21-19 06:23AM  
Oct-16-19 09:16AM  
08:39AM  
Oct-01-19 07:30AM  
Sep-26-19 07:30AM  
Sep-23-19 09:51AM  
Sep-09-19 07:30AM  
Aug-05-19 04:05PM  
Jul-17-19 06:51AM  
Jul-15-19 07:30AM  
Jul-10-19 10:27AM  
Jul-01-19 07:35AM  
Jun-27-19 12:55PM  
Jun-04-19 07:30AM  
May-30-19 07:30AM  
May-28-19 07:30AM  
May-20-19 07:30AM  
May-17-19 09:05AM  
May-16-19 09:00AM  
May-15-19 08:38AM  
May-06-19 08:11AM  
Apr-30-19 07:30AM  
Apr-22-19 07:30AM  
Apr-03-19 09:16AM  
07:30AM  
Apr-01-19 07:40AM  
Mar-27-19 07:30AM  
Mar-25-19 10:00AM  
Mar-14-19 01:07PM  
07:30AM  
Mar-13-19 08:41AM  
Mar-11-19 09:57AM  
09:55AM  
Mar-07-19 08:18AM  
Feb-25-19 07:30AM  
Feb-01-19 07:30AM  
Jan-25-19 07:50AM  
Jan-04-19 07:30AM  
Dec-23-18 10:25PM  
Dec-14-18 07:30AM  
Dec-06-18 10:30AM  
Nov-12-18 07:30AM  
Nov-06-18 07:30AM  
Oct-18-18 08:35AM  
Sep-25-18 07:30AM  
Sep-21-18 03:32PM  
Sep-19-18 07:30AM  
Sep-14-18 07:30AM  
Sep-10-18 04:01PM  
Sep-06-18 11:00AM  
09:15AM  
Sep-05-18 04:02PM  
Aug-27-18 07:45AM  
Aug-07-18 07:30AM  
06:32AM  
Jul-31-18 07:00AM  
Jun-29-18 01:20AM  
Jun-25-18 07:35AM  
Jun-18-18 09:56AM  
May-31-18 07:30AM  
May-29-18 07:30AM  
May-16-18 07:30AM  
May-07-18 07:30AM  
May-02-18 07:30AM  
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Yea ChristopherChief Development OfficerFeb 05Sale17.101001,71082,869Feb 07 05:18 PM
Feener Edward P.Chief Scientific OfficerFeb 05Sale17.111001,71196,634Feb 07 05:17 PM
Crockett Thomas AndrewCEOFeb 05Sale17.052003,410238,220Feb 07 05:14 PM
Yea ChristopherChief Development OfficerDec 20Option Exercise0.002,6461185,615Dec 26 05:32 PM
Yea ChristopherChief Development OfficerDec 20Sale17.022,64645,02582,969Dec 26 05:32 PM
Crockett Thomas AndrewCEODec 20Sale17.022,30039,150238,420Dec 26 05:30 PM
Yea ChristopherChief Development OfficerDec 16Option Exercise0.003,0101385,979Dec 16 07:34 PM
Yea ChristopherChief Development OfficerDec 16Sale17.053,01051,31882,969Dec 16 07:34 PM
Crockett Thomas AndrewCEODec 16Sale17.065,40092,116240,720Dec 16 07:32 PM
Yea ChristopherChief Development OfficerDec 13Option Exercise0.001,500684,469Dec 16 07:34 PM
Crockett Thomas AndrewCEODec 13Sale17.062,20037,536246,120Dec 16 07:32 PM
Yea ChristopherChief Development OfficerDec 13Sale17.051,50025,56882,969Dec 16 07:34 PM
Yea ChristopherChief Development OfficerDec 12Option Exercise0.00199183,168Dec 16 07:34 PM
Yea ChristopherChief Development OfficerDec 12Sale17.001993,38382,969Dec 16 07:34 PM
Crockett Thomas AndrewCEODec 12Sale17.001001,700248,320Dec 16 07:32 PM
SOLAND DANIEL BDirectorSep 27Buy11.877,96294,49810,000Sep 30 05:23 PM
SOLAND DANIEL BDirectorSep 26Buy11.902,03824,2522,038Sep 30 05:23 PM